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Summary 
Background: C-Myc is one of the major cellular oncogenes
overexpressed in non-small cell lung carcinoma (NSCLC).
Its deregulated expression is necessary but not sufficient for
malignant transformation. We evaluated expression of MYC
gene in NSCLC patients and its association with alterations
in the genes previously identified to be related to NSCLC
pathogenesis, PHACTR3 and E2F4.
Methods: We analyzed MYC gene expression by qRT-PCR
in 30 NSCLC patients’ samples and paired normal lung tis-
sue. MYC expression was further statistically evaluated in
relation to histopathological parameters, PHACTR3 and
E2F4 gene alterations and survival. Alterations in afore-
mentioned genes were previously detected and identified
based on AP-PCR profiles of paired normal and tumor
DNA samples, selection of DNA bands with altered mobil-
ity in tumor samples and their characterization by the ream-
plification, cloning and sequencing.
Results: MYC expression was significantly increased in
NSCLC samples and its overexpression significantly associ-
ated with squamous cell carcinoma subtype. Most impor-
tantly, MYC overexpression significantly coincided with
mutations in PHACTR3 and E2F4 genes, in group of all
patients and in squamous cell carcinoma subtype. More -
over, patients with jointly overexpressed MYC and altered
PHACTR3 or E2F4 showed trend of shorter survival.
Kratak sadr`aj
Uvod: C-Myc je jedan od glavnih }elijskih onkogena koji je
prekomerno eksprimiran kod nesitno}elijskog karcinoma
pluca (NSCLC). Promene u ekspresiji ovog onkogena iako
neophodne nisu dovoljne za malignu transformaciju. U
ovoj studiji smo prou~avali promene ekspresije MYC gena
kod pacijenata sa NSCLC kao i me|upovezanost sa pro -
menama u genima PHACTR3 i E2F4, za koje je ranije po -
ka zano da su povezani sa patogenezom NSCLC.
Metode: Ekspresija gena MYC je analizirana qRT-PCR meto -
 dom u uzorcima tumorskog i odgovaraju}eg normalnog plu} -
nog tkiva 30 pacijenata obolelih od NSCLC. Promene MYC
ekspresije su dalje analizirane u odnosu na histopatolo{ke
para metre, promene u genima PHACTR3 i E2F4, kao i u
odnosu na pre`ivljavanje pacijenata. Mutacije u pomenutim
genima su prethodno otkrivene i identifikovane na osnovu
uporedne analize AP-PCR profila parova normalnih i tumor -
skih DNK uzoraka, odabira DNK traka sa izmenjenom po -
kretljivo{cu u tumorskim uzorcima, i zatim njihovom karakter-
izacijom pomo}u reamplifikacije, kloniranja i sekvenciranja.
Rezultati: Ekspresija gena MYC je pove}ana u uzorcima
NSCLC i predstavlja zna~ajnu karakteristiku karcinoma
skva moznih celija. Prekomerna ekspresija ovog gena asoci-
ra sa prisustvom mutacija u genima PHACTR3 i E2F4 u
celoj grupi pacijenata, kao i u podgrupi karcinoma skva-
moznih }elija. Tako|e, pacijenti sa pove}anom ekspresijom
List of abbreviations: NSCLC, non-small cell lung carcinoma;
qRT-PCR, quantitative real time polymerase chain reaction,
AP-PCR, arbitrarily primed polymerase chain reaction; ACTB,
beta-actin; PHACTR3, phosphatase and actin regulator 3/
scaffold-associated PP1 inhibiting protein.
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Introduction
For more than 3 decades lung cancer has been
the most common type of human malignancies, rep-
resenting approximately 12–13% of all newly diag-
nosed cancer cases worldwide (1, 2). The estimated
number of lung cancer related deaths has been con-
stantly rising during this period (2). Although there
have been improvements in lung cancer patient sur-
vival, it is still very poor with less than 18% 5-year sur-
vival rate (3). Therefore, scientists are persistently
looking for novel and reliable molecular markers to
improve diagnosis of lung cancer, optimize treat-
ments and enable monitoring disease progression
and response to therapy. Molecules that regulate cel-
lular processes essential for maintaining malignant
phenotype, such as c-Myc oncogene, stand out as
promising candidates to serve as molecular markers.
This nuclear phosphoprotein functions as transcrip-
tional regulator of multiple genes and controls cell
proliferation, induces apoptosis, and regulates stem-
ness, senescence, metabolism and genome stability
(4). Its expression is deregulated in number of human
cancers including breast cancer, Burkitt’s lymphoma,
medulloblastoma, neuroblastoma and lung cancer
(5). In most studies on non-small cell lung carcinoma
(NSCLC), a predominant clinical form of lung cancer,
c-Myc protein is overexpressed in 40–75% of cases
(6–9). Even though it is highly expressed in NSCLC, it
does not associate with histopathological parameters
and its prognostic value for this type of lung cancer is
not clear (7, 9, 10). These data implicate that c-Myc
is important for NSCLC pathogenesis but not suffi-
cient to individually drive this process. Accordingly, we
evaluated expression of MYC gene in 30 NSCLC
patients’ samples and analyzed its association with
histopathological parameters and patients survival.
Our main focus was to investigate the possible asso-
ciation of MYC expression with alterations in the
genes previously identified to be related with NSCLC
pathogenesis, PHACTR3 and E2F4 (11). The aim
was to determine their mutual importance for NSCLC
pathogenesis and potential to serve as molecular
markers of this disease. Association analyses of MYC
overexpression and aforementioned gene alterations
were performed on whole set of patients’ samples
and samples stratified according to histopathological
parameters. To evaluate their joint prognostic signif-
cance we analyzed their effects on patients’ survival.  
Materials and Methods
Tissue samples
We analyzed paired tumor samples and adjacent
normal lung tissue from 30 patients with NSCLC who
underwent surgery at the Clinic for Thoracic Surgery
(Belgrade, Serbia). The specimens were frozen in liq-
uid nitrogen, where they were kept until DNA and
RNA extraction. The samples were collected and
used after obtaining patients’ informed consents and
approval from the Ethics Committee, in accordance
with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments.
Diagnosis of NSCLC and its classification according
to histological subtype, grade stage, and lymph node
invasion were established by histological analyses of
the surgical specimens. Distribution of all specimens
by relevant histopathological parameters was present-
ed previously (11). Overall, 9 adenocarcinomas and
21 squamous cell carcinomas were included in the
study. 26 NSCLC samples were well to moderately
differentiated (grade 1/2), while 4 were poorly differ-
entiated (grade 3). 16 samples were in early patho-
logical stages (stages I/II), and 14 cases were in late
stage (stage III). Lymph node invasion was observed
in 25 samples. Neither pre-surgical chemotherapy
nor radiotherapy had been administered.
RNA extraction and Reverse Transcription
Total RNA was isolated from tumor and corre-
sponding normal tissues samples of all 30 NSCLC
patients. The isolation was carried out using Trizol®
reagent (Invitrogen Life Technologies, USA) accord-
ing to the manufacturer’s instructions. RNA was
quantified by spectrophotometry and quality was ver-
ified by agarose gel electrophoresis. Subsequently,
reverse transcription reactions were performed using
2 mg of total RNA, with a High-capacity cDNA reverse
transcription kit (Applied Biosystems), following the
manufacturer’s protocol.
Quantitative real-time PCR
Quantitative real time PCR (qRT-PCR) was per-
formed to evaluate the mRNA expression level of
MYC gene. PCR reactions with 100 ng of cDNA were
Conclusions: Overall, MYC is frequently overexpressed in
NSCLC and it is associated with mutated PHACTR3 gene,
as well as mutated E2F4 gene. These joint gene alterations
could be considered as potential molecular markers of
NSCLC and its specific subtypes. 
Keywords: E2F4, MYC, Non-small cell lung carcinoma,
PHACTR3
MYC gena i istovremeno mutiranim PHACTR3 ili E2F4
genima su pokazali trend kra}eg pre`ivljavanja.
Zaklju~ak: Pove}ana ekspresija MYC gena je prisutna sa
visokom u~estalo{}u kod NSCLC i povezana je sa mutira -
nim PHACTR3 genom, kao i mutiranim E2F4 genom. Ove
zdru`ene genske promene se mogu razmatrati kao poten-
cijalni molekularni markeri NSCLC i njegovih specifi~nih
podtipova.
Klju~ne re~i: E2F4, MYC, nesitno}elijski karcinom plu}a,
PHACTR3
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performed using pair of primers specific for MYC
transcripts (12). For each sample ACTB was used as
a reference gene for the normalization of target gene
expression (13). The primer sequences were as fol-
lows: 5’-CAA GAG GCG AAC ACA CAA CGT CT-3’
(sense) and 5’-AAC TGT TCT CGT CGT TTC CGC
AA-3’ (antisense) for MYC, and 5 -TGG ACA TCC
GCAAAG ACC TGT AC-3  (sense) and 5-TCA GGA
GGA GCA ATG ATC TTG A-3  (antisense) for the
ACTB. PCR reactions were performed using a Ma -
xima SYBR Green/ROX qPCR Master Mix (Thermo
Fisher Scientific, USA) on a QuantStudio 3 Real-Time
PCR system (Thermo Fisher Scientific, USA) accord-
ing to the manufacturer’s recommendations. Each
sample was tested in triplicate and relative gene
expres sion levels were analyzed by the 2−DDCt
method (14).
Identification of NSCLC associated genes 
In our preceding study we identified several
genes not previously related to NSCLC pathogenesis
(11). Overall procedure of identifying those genes
included: DNA isolation, generation and comparison
of AP-PCR profiles of paired normal and tumor DNA
samples, selection of DNA bands with altered mobility
in tumor versus matching normal samples and their
further characterization through the reamplification,
cloning and sequencing.
DNA extraction
DNA was extracted using the phenol/chloro-
form/isoamyl alcohol method (15). The quality of the
DNA was verified by electrophoresis on 0.8% agarose
gel and staining with ethidium bromide. The DNA con -
centration was established spectrophotometrically.
AP-PCR DNA fingerprinting
AP-PCR (Arbitrarily Primed Polymerase Chain
Reaction) was used to generate DNA fingerprint pro-
files of paired DNA samples, normal and tumor, of
the same patient (16). In short, six different, random-
ly chosen, primers were used to amplify DNA, initially
under low-stringency conditions and then at high-
stringency conditions, to generate informative finger-
prints of moderate complexity that could distinguish
tumor from normal tissue. The reactions were per-
formed in a GeneAmp® PCR System 9700 (Applied
Biosystems, Foster City, CA, USA) using PCR reaction
kits supplied by Fermentas Life Sciences (Lithuania).
Each reaction consisted of an initial denaturation step
(95 ˚C for 5 min), 4 cycles at low-stringency condi-
tions (specific for each primer), 35 cycles at high-
stringency conditions (specific for each primer), and a
final extension (72 ˚C for 7 min). Five out of six tested
primers (p53 A, MDR A, E5A p53, GAPDH A, and
GAPDH S) produced informative sequence alter-
ations differentiating normal from tumor tissue.
Primer sequences, AP-PCR amplification profiles and
Table I AP-PCR primer sequences, amplification profiles and reaction conditions.
Primers Sequences
Amplification profiles
Reaction conditionsLow-stringency 
conditions
High-stringency 
conditions
p53A 5’–TTG GGC AGT GCT CGC TTA GT–3’
95 °C 30”; 40 °C 2’; 
72 °C 1’
95 °C 30”; 60 °C 2’; 
72 °C 1’
0.2 mmol/L each dNTP
3.5 mmol/L MgCl2
5 mmol/L primer 
1U Taq DNA Polymerase
MDR A 5’–GTT CAA ACT TCT GCT CCT GA–3’
95 °C 30”; 40 °C 2’; 
72 °C 1’
95 °C 30”; 58 °C 2’; 
72 °C 1’
0.4 mmol/L each dNTP
2.5 mmol/L MgCl2
5 mmol/L primer
1U Taq DNA Polymerase
E5A p53 5’–CAG CCC TGT CGT CTC TCC AG–3’
95 °C 30”; 40 °C 2’; 
72 °C 1’
95 °C 30”; 55 °C 2’; 
72 °C 1’
0.6 mmol/L each dNTP
3.5 mmol/L MgCl2
3 mmol/L primer 
1U Taq DNA Polymerase
GAPDH A 5’–AGC CTT CTC CAT GGT GGT GAA GAC–3’
95 °C 30”; 50 °C 2’; 
72 °C 1’
95 °C 30”; 72 °C 2’; 
72 °C 1’
0.2 mmol/L each dNTP
2.5 mmol/L MgCl2
3 mmol/L primer
1U Taq DNA Polymerase
GAPDH S 5’–CGG AGT CAA CGG ATT TGG TCG TAT–3’
95 °C 30”; 50 °C 2’; 
72 °C 1’
95 °C 30”; 70 °C 2’; 
72 °C 1’
0.4 mmol/L each dNTP
2.5 mmol/L MgCl2
5 mmol/L primer
1U Taq DNA polymerase
reaction conditions are described in our previous pub-
lications (16, 11) and summarized in Table I. The AP-
PCR products were separated on 6–8% non-denatur-
ing polyacrylamide gels and visualized by silver
staining.
Isolation, cloning and sequencing of altered
bands
Some of the DNA bands with altered mobility, in
tumor compared to normal samples, were selected
for further characterization. Briefly, PCR amplicons of
chosen bands were scrapped from silver stained gels
with a hypodermic 22-gauge needle previously
soaked in the PCR master mix solution. The needle
was dipped in the PCR master mix for 2 min and then
discarded. Further reamplification of the PCR prod-
ucts was performed with the same primers used for
AP-PCR reactions at high-stringency conditions spe-
cific for each particular primer. The obtained products
were cloned and sequenced as described (11). In
short, the reamplified material was administrated on
1.5% agarose gels, than purified using DNA
Extraction Kit (Fermentas Life Sciences, Lithuania)
and cloned with GeneJetTM PCR Cloning Kit (Fer -
mentas Life Sciences, Lithuania) according to manu-
facturers’ instructions. After cloning procedure, plas-
mids were purified using GeneJetTM Plasmid
Mini prep Kit (Fermentas Life Sciences, Lithuania).
Further, sequencing was performed in both directions
on several clones for each selected DNA band on an
ABI Prism 3130 Genetic Analyzer automated sequ -
encer (Applied Biosystems, Foster City, CA, USA)
using BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA, USA). The
obtained sequences were analyzed using BLAST soft-
ware in the NCBI GenBank and EBI (Sanger Institute)
database to identify selected alterations. 
Statistical analysis
Significant differences between the data sets
were determined by GraphPad Prism 6 software (La
Jolla, CA USA) and statistical package R (version
3.1.3 (2015-03-09) Copyright (C) 2015 The R
Foundation for Statistical Computing). Paired t-test
was used to assess statistical differences in expression
level of MYC gene between paired tumor and normal
sample of each patient. On the other hand, difference
in MYC relative expression level between total tumor
and normal samples was evaluated using unpaired t-
test. Fisher exact test was used to examine the rela-
tionship between histopathological parameters (histo-
logical subtype, grade stage, and lymph node
invasion) and MYC overexpression. The same statisti-
cal analysis was used to study the possible associa-
tions between frequencies of MYC overexpression
and alterations in PHACTR3 and E2F4. Survival
analyses were performed by Kaplan & Meier product-
limit method. The log rank test was used to evaluate
the significance of the difference between pairs of
survival probabilities. Overall survival rate was calcu-
lated from day one after surgery to the last follow-up
examination or death of the patient. The total follow
up period was 117 months. Statistical differences
were considered significant when p value was <
0.05.
Results
MYC gene expression analysis
Alterations in MYC gene expression between
tumor and matching normal samples were analyzed
by qRT-PCR. MYC gene expression was significantly
higher in NSCLC samples (p=0.018) compared with
normal lung samples (Figure 1). Specifically, MYC
gene was overexpressed in 11 out of 30 tumor sam-
ples (37%). 
Increased MYC gene expression in relation to
histopathological parameters 
Significance of MYC overexpression was initially
evaluated in relation to major histopathological
parameters: NSCLC subtype, histological grade, stage
and lymph node invasion (Table II). Statistical analy-
ses revealed that MYC overexpression was significant-
ly associated with histological subtype (p=0.01). In
adenocarcinoma increased MYC expression was
completely absent (0/9), while in squamous cell car-
cinoma MYC overexpression was more frequently
present (11/21, 52.4%). 
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Figure 1 MYC gene expression. Box plot analysis of MYC
expression level in primary tumor (T) and normal (N) sam-
ples. Results are presented as log2 of MYC gene expression
relative to ACTB gene level. * indicates p<0.05 as signifi-
cant gene overexpression in tumor samples compared to
normal samples. 
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Increased MYC gene expression in relation to
gene alterations
We further examined MYC expression in relation
to the presence of alterations in PHACTR3 and E2F4.
In previous study (11), mutations in these two genes
were identified according to sequence data and
BLAST search results. Specifically, multiple nucleotide
substitutions were detected in PHACTR3 and E2F4.
Association between MYC overexpression and
altered PHACTR3 gene 
Patients with altered PHACTR3 gene had more
frequently increased MYC gene expression (Table III;
p=0.015). Among six patients with altered PHACTR3
gene, 5 (83.3%) had increased MYC mRNA level,
while in 1 patient (16.7%) MYC was not over expres -
sed. Similar association was present in subgroup of
patients with squamous cell carcinoma (Table III;
p=0.035). In this group all patients with PHACTR3
alterations had overexpressed MYC.
Association between MYC overexpression and
altered E2F4 gene
MYC overexpression in the presence of E2F4
gene alterations showed the same pattern of conjunc-
tion as with the incidence of altered PHACTR3 gene
(Table III). Namely, 83.3% of patients with abnormal
E2F4 had overexpressed MYC compared to 16.7% of
patients that did not show overexpression of this
oncogene (p=0.015). In squamous cell carcinoma
subtype altered E2F4 exclusively coincided with MYC
overexpression (100%) while unchanged E2F4 was
predominantly associated with non-overexpressed
MYC (62.5% versus 37.5%; p=0.035).
Table II Association between MYC overexpression and
histopathological parameters.
Table III Association of overexpressed MYC oncogene with altered PHACTR3 and E2F4 genes.
ag1/2, well to moderately differentiated; g3, poorly differen-
tiated; bNP, number of patients per group; cbold indicates sta-
tistically significant value, p<0.05.
Parameter Total NPb
MYC overexpression
Yes 
NP (%)
No 
NP (%)
p
value
Total 30 11 19
NSCLC subtype
Adenocarcinoma 9 0 (0.0) 9 (100.0) 0.01c
Squamous cell 
carcinoma 21 11 (52.4) 10 (47.6)
Histological gradea
g1/2 26 11 (42.3) 15 (57.7) 0.36
g3 4 0 (0.0) 4 (100.0)
Stage
I/II 16 6 (37.5) 10 (62.5) 1
III 14 5 (35.7) 9 (64.3)
Lymph node invasion
Positive 25 9 (36.0) 16 (64.0) 1
Negative 5 2 (40.0) 3 (60.0)
MYC overexpression
Squamous cell carcinoma
MYC overexpression
Yes No Yes No
NPa (%) NP (%) NPa (%) NP (%)
PH
A
C
TR
3
al
te
ra
tio
n Yes 5 (83.3) 1 (16.7) 5 (100.0) 0 (0.0)
No 6 (25.0) 18 (75.0) 6 (37.5) 10 (62.5)
p value 0.015b 0.035
E2
F4
al
te
ra
tio
n Yes 5 (83.3) 1 (16.7) 5 (100.0) 0 (0.0)
No 6 (25.0) 18 (75.0) 6 (37.5) 10 (62.5)
p value 0.015b 0.035
aNP, number of patients per group; bbold indicates statistically significant values, p<0.05.
Effects of gene alterations and MYC 
overexpression on survival rate
Kaplan-Meier survival curves were analyzed to
evaluate the effect of MYC gene overexpression in the
presence of aforementioned gene alterations on
NSCLC patients’ survival. When individually exam-
ined, MYC overexpression did not significantly affect
the survival rate (Figure 2A; p=0.646). However,
when considered in combination with altered PHAC-
TR3 and E2F4, MYC overexpression showed tenden-
cy towards shorter survival although did not reach sta-
tistical significance. The median survival time was 1
month for patients with overexpressed MYC and
altered PHACTR3 or E2F4 compared to 7.5 months
for those with overexpressed MYC only (Figure 2B and
C; p=0.138). 
Discussion
C-Myc is one of the most important cellular
oncogenes necessary for malignant transformation
(17). Deregulation of its expression is critical for the
pathogenesis of various cancer types, including lung
cancer (5). C-Myc protein is overexpressed in 40–
75% of NSCLC patients (6–9). However, data
obtained by RT-PCR are not consistent. Wu et al. have
reported only 18% NSCLC cases with MYC overex-
pression (18), while Hsu and colleagues have found
overexpressed MYC in 91% of NSCLC patients’ sam-
ples (19). In our study, we evaluated MYC gene
expression by qRT-PCR analysis in 30 NSCLC
patients’ samples and observed its overexpression in
37% of cases. This result corresponds to most studies
on c-Myc protein expression (7, 20). Moreover, we
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Figure 2 Kaplan–Meier overall survival analyses. No difference in survival was observed between patients with overexpressed
(MYC+) and non-overexpressed MYC gene (MYC-) (A). Patients with overexpressed MYC and mutated E2F4 (MYC+/ E2F4+)
(B) or PHACTR3 (MYC+/ PHACTR3+) (C) showed trend of decreased survival compared to those with overexpressed MYC
only (MYC+/ E2F4-, MYC+/ PHACTR3-). 
have observed for the first time that MYC overexpres-
sion is a significant characteristic of squamous cell
carcinoma subtype rather than adenocarcinoma. C-
Myc overexpression was previously shown to be more
frequently present in squamous cell carcinoma but
without statistical significance (9), while Xu et al. (8)
reported it to be significant characteristic of adenocar-
cinoma.
Major focus of this study was to analyze MYC
gene overexpression in relation to alterations in genes
associated with NSCLC pathogenesis (11). Tested
gene alterations, PHACTR3 and E2F4 were shown to
be associated with MYC overexpression. Moreover,
these alterations significantly coincide with MYC over-
expression in squamous cell carcinoma. PHACTR3
(Phosphatase and actin regulator 3/ scaffold-associ-
ated PP1 inhibiting protein), also known as scapinin,
is a protein phosphatase 1-binding protein associated
with nuclear non-chromatin structures (the nuclear
matrix or nucleoskeleton) (21). It directly interacts
with actin and regulates actin cytoskeleton structures
influencing cell spreading and motility (22). At the
same time, nuclear F-actin activates transcription of c-
Myc through Wnt/b-catenin signaling (23). We spec-
ulate that actin could be one of potential interconnec-
tions between PHACTR3 alterations and MYC
overexpression. In our previous study PHACTR3 was
shown to be altered in 6 out of 30 patients, mostly
with squamous cell carcinoma (11). Recently, signifi-
cance of PHACTR3 as parameter for non-invasive
lung cancer diagnosis was evaluated along with other
diagnostic and risk biomarkers (24).
Considering interrelationship between MYC
overexpression and mutational status of E2F4 the
observed positive association is not surprising. E2F4 is
a part of complex involved in repression of MYC tran-
scription in response to different signals (25). This
transcriptional regulator was shown to be necessary
for normal development of lung tissue (26). However,
its importance and role in pathogenesis of NSCLC
was examined only in our earlier publication (11). In
that study, altered E2F4 was detected in 20% of
patients, predominantly with squamous cell carcino-
ma. 
The influence of c-Myc overexpression on
NSCLC patient survival is inconclusive. Some authors
showed c-Myc association with shorter survival (9),
while others reported no effects on NSCLC prognosis
(7). We observed no significant difference in life span
between NSCLC patients with overexpressed and
non-overexpressed MYC gene. However, the pres-
ence of altered PHACTR3 or E2F4 along with overex-
pressed MYC contributed to shorter survival but with-
out prognostic significance. Considering our previous
results this joint effect of MYC and altered genes
could be mainly attributed to the significant negative
effects of altered PHACTR3 and E2F4 genes on
NSCLC patients’ survival (11).
Overall this study implicates frequent presence
of overexpressed MYC gene in NSCLC patients and
its applicative potential as molecular marker of squa-
mous cell carcinoma. Additionally, the results point
out the relevance of overexpressed MYC in associa-
tion with altered PHACTR3 and E2F4 genes as joint
molecular markers of NSCLC and its specific sub-
types. Most importantly, we identified positive associ-
ations between MYC overexpression and aforemen-
tioned gene alterations not previously considered in
NSCLC nor other cancer types, therefore opening a
novel research perspective in studying c-Myc role in
carcinogenesis. In this context, functional intercon-
nection of MYC and altered genes will be of particular
interest in our further studies.
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